Sandhya Nair

927 total citations
52 papers, 647 citations indexed

About

Sandhya Nair is a scholar working on Hematology, Molecular Biology and Rheumatology. According to data from OpenAlex, Sandhya Nair has authored 52 papers receiving a total of 647 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 13 papers in Molecular Biology and 13 papers in Rheumatology. Recurrent topics in Sandhya Nair's work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (11 papers) and Rheumatoid Arthritis Research and Therapies (10 papers). Sandhya Nair is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (11 papers) and Rheumatoid Arthritis Research and Therapies (10 papers). Sandhya Nair collaborates with scholars based in United States, Belgium and Netherlands. Sandhya Nair's co-authors include Paco M J Welsing, J. W. J. Bijlsma, N.S. Remya, F.P.J.G. Lafeber, Prabha D. Nair, Jacob M. van Laar, Maneesha Mehra, Floris P. J. G. Lafeber, Saad Z. Usmani and Annette Lam and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sandhya Nair

45 papers receiving 636 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandhya Nair United States	13	240	207	149	144	130	52	647
Paola Masolini Italy	17	165 0.7×	389 1.9×	252 1.7×	157 1.1×	294 2.3×	24	849
Laura Pirilä Finland	16	257 1.1×	76 0.4×	123 0.8×	99 0.7×	74 0.6×	47	649
Peter Noertersheuser United States	10	165 0.7×	118 0.6×	141 0.9×	181 1.3×	63 0.5×	22	626
Kazuko Hirabayashi Japan	12	128 0.5×	213 1.0×	340 2.3×	84 0.6×	58 0.4×	27	783
Amit Agarwal United States	18	146 0.6×	376 1.8×	372 2.5×	85 0.6×	360 2.8×	86	993
Shilpa Paul United States	13	75 0.3×	294 1.4×	122 0.8×	50 0.3×	232 1.8×	41	670
Kathleen Shields United States	11	75 0.3×	85 0.4×	148 1.0×	153 1.1×	91 0.7×	33	634
Tadahiko Igarashi Japan	14	97 0.4×	143 0.7×	131 0.9×	59 0.4×	296 2.3×	45	577
Daniela Belotti Italy	11	111 0.5×	461 2.2×	167 1.1×	185 1.3×	76 0.6×	19	711
Renato Alterini Italy	16	45 0.2×	102 0.5×	86 0.6×	128 0.9×	185 1.4×	42	840

Countries citing papers authored by Sandhya Nair

Since Specialization

Citations

This map shows the geographic impact of Sandhya Nair's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandhya Nair with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandhya Nair more than expected).

Fields of papers citing papers by Sandhya Nair

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandhya Nair. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandhya Nair. The network helps show where Sandhya Nair may publish in the future.

Co-authorship network of co-authors of Sandhya Nair

This figure shows the co-authorship network connecting the top 25 collaborators of Sandhya Nair. A scholar is included among the top collaborators of Sandhya Nair based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandhya Nair. Sandhya Nair is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Usmani, Saad Z., Thierry Façon, Vânia Hungria, et al.. (2025). Efficacy of Daratumumab-Bortezomib-Lenalidomide-Dexamethasone (DVRd) vs Daratumumab-Lenalidomide-Dexamethasone (DRd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma Myeloma & Leukemia. 25. S308–S308.

Dhakal, Binod, Hermann Einsele, Jordan M. Schecter, et al.. (2024). Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database. Blood Advances. 8(19). 5062–5071. 3 indexed citations

Ye, Jing Christine, Noa Biran, Sandhya Nair, et al.. (2024). P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S100. 1 indexed citations

Krishnan, Amrita, Ajay K. Nooka, Ajai Chari, et al.. (2023). Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of Comparative Effectiveness Research. 12(6). e220186–e220186. 8 indexed citations

Fonseca, Rafaël, Thierry Façon, Mahmoud Hashim, et al.. (2023). Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma. The Oncologist. 28(5). e263–e269. 16 indexed citations

Maisnar, Vladimír, Luděk Pour, Ivan Špıčka, et al.. (2022). Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. Clinical Lymphoma Myeloma & Leukemia. 23(2). 145–153. 4 indexed citations

Barreto, Deirisa Lopes, et al.. (2022). Defining the care delivery value chain and mapping the patient journey in rheumatoid arthritis. Rheumatology International. 43(4). 743–750. 3 indexed citations

Mease, Philip J., Iain B. McInnes, Lai‐Shan Tam, et al.. (2021). Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Lara D. Veeken. 60(5). 2109–2121. 42 indexed citations

Fonseca, Rafaël, Thierry Façon, Mahmoud Hashim, et al.. (2021). First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios. Blood. 138(Supplement 1). 118–118. 6 indexed citations

10.

Weisel, Katja, Thomas G. Martin, Amrita Krishnan, et al.. (2021). Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Clinical Drug Investigation. 42(1). 29–41. 19 indexed citations

11.

Fonseca, Rafaël, Saad Z. Usmani, Maneesha Mehra, et al.. (2020). Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 20(1). 1087–1087. 67 indexed citations

12.

Nair, Sandhya, et al.. (2017). Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. International Journal of Ophthalmology. 10(8). 1251–1254. 8 indexed citations

13.

Nair, Sandhya, Johannes W. G. Jacobs, Marije F. Bakker, et al.. (2016). Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach. PLoS ONE. 11(3). e0148791–e0148791. 12 indexed citations

14.

Nair, Sandhya, Roel J.H. Custers, Jacob M. van Laar, et al.. (2016). Knee joint distraction compared to total knee arthroplasty for treatment of end stage osteoarthritis: simulating long-term outcomes and cost-effectiveness. Osteoarthritis and Cartilage. 24. S426–S427. 3 indexed citations

15.

Nair, Sandhya, Paco M J Welsing, Ivy Y. Choi, et al.. (2016). A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients. PLoS ONE. 11(3). e0152362–e0152362. 21 indexed citations

16.

Nair, Sandhya, et al.. (2016). Knee Joint Distraction Compared to Total Knee Arthroplasty for Treatment of End Stage Osteoarthritis: Simulating Long-Term Outcomes and Cost-Effectiveness. PLoS ONE. 11(5). e0155524–e0155524. 30 indexed citations

17.

Welsing, Paco M J, Jan J. Sprengers, J. W. J. Bijlsma, et al.. (2015). Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Lara D. Veeken. 55(5). 826–839. 62 indexed citations

18.

Nair, Sandhya, Paco M J Welsing, J. W. J. Bijlsma, et al.. (2015). Does disease activity add to functional disability in estimation of utility for rheumatoid arthritis patients on biologic treatment?. Lara D. Veeken. 55(1). 94–102. 5 indexed citations

19.

Spil, W.E. van, et al.. (2014). Systemic biochemical markers of joint metabolism and inflammation in relation to radiographic parameters and pain of the knee: data from CHECK, a cohort of early-osteoarthritis subjects. Osteoarthritis and Cartilage. 23(1). 48–56. 33 indexed citations

20.

Krieckaert, C., Sandhya Nair, Michael T. Nurmohamed, et al.. (2013). Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Annals of the Rheumatic Diseases. 74(2). 361–368. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact